Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing2021-04-27T17:17:21-07:00April 20th, 2021|Read more
Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers2021-02-11T19:51:54-08:00November 25th, 2020|Read more
Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status2021-02-11T19:57:34-08:00November 22nd, 2020|Read more
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing2021-02-17T18:10:07-08:00November 17th, 2020|Read more
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma2021-02-11T20:05:42-08:00October 30th, 2020|Read more
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels2021-02-26T19:12:15-08:00May 9th, 2018|Read more
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations2021-02-26T19:12:23-08:00May 8th, 2018|Read more
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software2026-10-21T19:23:02-07:00November 7th, 2017|Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.2026-10-21T19:20:01-07:00August 1st, 2017|Read more
FDA approves new combination treatment for acute myeloid leukemia2021-02-26T19:12:55-08:00April 28th, 2017|Read more
